BioMedNewsBreaks

TuesdayApr 02, 2024 11:45 am

BioMedNewsBreaks — Astiva Health Setting New Standard for Patient-Centric Care

Astiva Health, a leading provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is championing a model of care that emphasizes proactive health management and a healthy lifestyle over traditional reactive methods. “At the core of Astiva Health’s innovative approach is the principle of patient-centric care. This method prioritizes the active involvement of patients in their healthcare decisions, ensuring their preferences, needs and values guide their care plans… A critical element in Astiva Health’s strategy is the development of a supportive health community. This community – encompassing healthcare professionals, family, caregivers, and peer groups – provides…

Continue Reading

MondayApr 01, 2024 3:31 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Year-End 2023 Financial Report, Business Update

  Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial-intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the year ended Dec. 31, 2023; the company also released a corporate update. The report noted POAI experienced a net loss of some $14 million on total revenue of approximately $1.8 million for the year; the company also reported a 50% reduction in basic and diluted net loss per common share for the full year 2023.…

Continue Reading

MondayApr 01, 2024 1:52 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Begins Manufacturing for Major Sports Brand Licensee

Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a specific focus on transdermal technologies, today announced it has been engaged by and received a first order from Fit For Life Group (“FFL”), a major brand license holder. Nutriband expects a fully executed supplier agreement to follow. Under the agreement Nutriband’s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer. “This purchase order from FFL allows Nutriband and our contract manufacturing subsidiary, Active Intelligence, to once again demonstrate our capabilities in the development and manufacturing of innovative products,” said Gareth Sheridan, CEO of Nutriband. “We are excited to continue…

Continue Reading

WednesdayMar 27, 2024 2:01 pm

BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Making Drugs Perform Better

Sigyn Therapeutics (OTCQB: SIGY), a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer therapies. “The company’s lead product candidate, Sigyn Therapy(TM), is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (‘CRRT’) machines already installed in hospitals and clinics. The device incorporates a formulation of adsorbent components to optimize the broad-spectrum reduction of viral pathogens, bacterial toxins and inflammatory mediators from the bloodstream,” a…

Continue Reading

TuesdayMar 26, 2024 3:47 pm

BioMedNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Expands Technology E-Commerce Portfolio Through Strategic Acquisition

NextPlat (NASDAQ:NXPL, NXPLW), a global e-commerce provider, today announced the significant expansion of its North American e-commerce business with the acquisition of Outfitter Satellite Inc. through an all-cash transaction. According to the announcement, the transaction is expected to close on April 1, 2024. “Outfitter is an ideal addition to our technology e-commerce portfolio, delivering immediate synergies and value, quickly and profitably adding scale to our North American operations,” said Charles M. Fernandez, executive chairman and CEO of NextPlat. “Through acquisitions such as Outfitter and the introduction of new technology and healthcare e-commerce offerings expected later this year, we are executing…

Continue Reading

MondayMar 25, 2024 3:24 pm

BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate

Lumos Pharma (NASDAQ: LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (“PGHD”) through phase 2 clinical trials, has received a notice of allowance for a submitted patent. The notice was received from the U.S. Patent and Trade Office (“USPTO”) earlier this month; the notice covers claims the company made for its patent titled “Compactable Oral Formulations of Ibutamoren.” According to the announcement, the patent includes improved formulations of LUM-201 that the company plans to use in its phase 3 trial and eventually commercialize. LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion…

Continue Reading

MondayMar 25, 2024 3:00 pm

BioMedNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Launches ‘Gold Standard’ of Mass Spectrometry into Narcotics Detection Market

Astrotech (NASDAQ: ASTC) and its wholly owned subsidiary, 1st Detect Corporation, today announced that the company is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (“NTD”). A high-performance laboratory instrument, the TRACER 1000 NTD is capable of rapid detection of trace levels of narcotic compounds in seconds. With the company’s Tracer 1000 Explosive Trace Detector (“ETD”) now found in multiple locations in 14 countries, the NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo, and infrastructure security, correctional facilities, military, and law enforcement. “Over the last five years our…

Continue Reading

MondayMar 25, 2024 11:31 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock. Pricing was $4.215 per share of common stock (or prefunded warrant) and accompanying warrant, resulting in approximately $6.5 million before deducting typical fees and offering expenses. According to the announcement, the warrants have an exercise price of $4.09 per share and…

Continue Reading

ThursdayMar 21, 2024 3:35 pm

BioMedNewsBreaks — Astiva Health Is Reshaping Healthcare Delivery

Astiva Health CEO Dr. Tri Nguyen was the featured guest in a recent Bell2Bell Podcast episode. “During the podcast, Nguyen provided an in-depth look at how Astiva Health is reshaping healthcare delivery, including an overview of the company’s commitment to patient involvement in healthcare and highlights of the company’s innovative strategies in offering comprehensive care… ‘So Astiva, other than providing full medical-care prescription drugs, we also focus on providing very rich supplemental benefits to our enrollees and getting them involved, participating and aiming for an active, healthy and meaningful life,’” reads a recent article, which contains quotes from the discussion.…

Continue Reading

ThursdayMar 21, 2024 12:34 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Financial Results, Corporate Highlights for Q4, FY 2023

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec. 31, 2023. According to the report, key achievements during the period included enrolling the first patients for a pivotal trial studying AIMIGo(TM) System for synthesizing a 12-lead ECG as well as clinical and regulatory progress made for the AIMIGo 3D VECG system. In addition, the company noted it had received two new patents during the period, covering HeartBeam’s proprietary technologies. “We have continued to make…

Continue Reading